Keyword: Baylor College of Medicine
The week’s biotech news included an eFFECTOR drug that slows liver cancer in mice and insight into age-related muscle decline.
Diagnostic maker Echosens is teaming up with a consortium of health systems to develop a real-world evidence model to help standardize care for NASH.
Last week’s biotech discoveries include a gut-coating pill that lowers glucose and prostate-tumor test to predict a good response to immunotherapy.
The agreement will give TapImmune control of adoptive T-cell therapies designed to provide more durable responses than CAR-Ts.
The past week ushered in news about a toxin in scorpion venom that may relieve RA and a skin bacterium with anti-cancer powers.
CRISPR is a promising treatment for blood disorders, but it comes with challenges, such as off-target effects.
Scientists at Baylor have discovered that when they silence a signaling pathway in the body called Hippo, they can reverse heart failure in mice.
A new target for the treatment of MeCP2 duplication syndrome could be useful in treating autism and other neurological conditions.
Normalizing the blood vessels that feed tumors and gaining a better understanding of how they interact with immune cells could improve cancer treatment, Baylor researchers report.
Cell Medica has raised £60 million ($74 million) to expand its clinical pipeline of cancer cellular immunotherapies.